| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief R&D Officer
1 company
Zalevsky Jonathan serves as a Chief R&D Officer at NKTR. Across recent SEC filings that breaks down to 0 buys and 34 sells. Those positions are worth an estimated $1.2M at current prices.
Historically, Zalevsky Jonathan's trades have earned a middling insider score of 63/100 across 23 rated trades. Over a 12-month horizon, 52.6% of those trades were profitable, with an average 12-month return of +1.3%.
The biggest single holding is NKTR (~$1.2M) as Chief R&D Officer. The recent filings there lean toward selling, a net 451,991 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2019 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 3,960 | $17.97 | $71,161.20 | -1.3% |